Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $688000.0.

  • Barinthus Biotherapeutics' Gains from Investment Securities rose 27916.67% to $688000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 55133.53%. This contributed to the annual value of $866000.0 for FY2024, which is 147454.55% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Gains from Investment Securities stood at $688000.0, which was up 27916.67% from -$340000.0 recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Gains from Investment Securities registered a high of $1.6 million during Q4 2021, and its lowest value of -$384000.0 during Q3 2024.
  • For the 5-year period, Barinthus Biotherapeutics' Gains from Investment Securities averaged around $244470.6, with its median value being $85000.0 (2023).
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Gains from Investment Securities surged by 388064.52% in 2024, and later plummeted by 198888.89% in 2025.
  • Barinthus Biotherapeutics' Gains from Investment Securities (Quarter) stood at $1.6 million in 2021, then tumbled by 80.79% to $317000.0 in 2022, then tumbled by 109.78% to -$31000.0 in 2023, then surged by 3880.65% to $1.2 million in 2024, then crashed by 41.3% to $688000.0 in 2025.
  • Its Gains from Investment Securities stands at $688000.0 for Q3 2025, versus -$340000.0 for Q2 2025 and $1000.0 for Q1 2025.